Veterinary Medicines

EURICAN DAP LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Authorised
  • Water for injection
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Download as PDF

Product identification

Medicine name:
EURICAN DAP LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION
EURICAN DAP LIOFILIZADO Y DISOLVENTE PARA SUSPENSIÓN INYECTABLE.
Active substance:
  • Water for injection
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Water for injection
    1.00
    millilitre(s)
    /
    1.00
    unit(s)
  • Canine distemper virus, strain BA5, Live
    4.00
    log10 cell culture infective dose 50
    /
    1.00
    unit(s)
  • Canine parvovirus, strain CAG2, Live
    4.90
    log10 cell culture infective dose 50
    /
    1.00
    unit(s)
  • Canine adenovirus 2, strain DK13, Live
    2.50
    log10 cell culture infective dose 50
    /
    1.00
    unit(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Spain
Package description:
  • Plastic box of 10 vials of lyophilisate (1 dose)
  • Plastic box of 50 vials of lyophilisate (1 dose)
  • Plastic box of 10 vials of solvent (1 ml)
  • Plastic box of 50 vials of solvent (1 ml)
  • Plastic box of 10 vials of lyophilisate (1 dose) and 10 vials of solvent (1 ml)
  • Plastic box of 50 vials of lyophilisate (1 dose) and 50 vials of solvent (1 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health Espana S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Spanish Agency For Medicines And Health Products
Authorisation number:
  • 3467 ESP
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0305/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 8/04/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 8/04/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 8/04/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."